title: [Expression and significance of Survivin mRNA in xenotransplanted nasopharyngeal carcinoma treated by paclitaxel combined with radiotherapy].
abstract: OBJECTIVE
  To investigate the expression and significance of Survivin mRNA in xenotransplanted nasopharyngeal carcinoma treated by paclitaxel combined with radiotherapy.
  
  
  METHODS
  Xenotransplanted nasopharyngeal carcinoma was established by CNE-2 cell line, then grouped and treated with paclitaxel, radiotherapy, paclitaxel combined with radiotherapy respectively. Xenotransplanted tumor volume was measured; tumor specimens were confirmed by routine hemotoxylin-eosin staining; apoptosis index was assayed by flow cytometry and Survivin mRNA was detected by one step RT-PCR.
  
  
  RESULTS
  Xenotransplanted tumor growth was significantly inhibited by paclitaxel combined with radiotherapy and its inhibition rate was 99.3%. Compared to control group, apoptosis index was apparently increased in the other three groups (P<0.05), especially in the combined therapy group (P<0.05). Survivin mRNA expression was obviously decreased in the combined therapy group (P<0.05); whereas there was no difference in its expression among the groups of paclitaxel, radiotherapy, and control group (P>0.05).
  
  
  CONCLUSIONS
  Paclitaxel combined with radiotherapy can induce significant killing effect in xenotransplanted nasopharyngeal carcinoma; paclitaxel can enhance the radiosensitivity of xenotransplanted nasopharyngeal carcinoma and its mechanism may rely on the down-regulation of Survivin expression.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China. zhang-shuaixn@163.com
authors.forename: Shuai
authors.initials: S
authors.lastname: Zhang
authors.forename: Jianyun
authors.initials: J
authors.lastname: Xiao
authors.forename: Suping
authors.initials: S
authors.lastname: Zhao
authors.forename: Yuanzheng
authors.initials: Y
authors.lastname: Qiu
authors.forename: Yong
authors.initials: Y
authors.lastname: Liu
authors.forename: Chenglong
authors.initials: C
authors.lastname: Wang
authors.forename: Yongquan
authors.initials: Y
authors.lastname: Tian
mesh_terms: D000818:Animals; D001918:Brachytherapy; D045744:Cell Line, Tumor; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism* / Q000628:therapy; D017239:Paclitaxel / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism*; D000077022:Survivin; D023041:Xenograft Model Antitumor Assays
chemical_list: C117749:Birc5 protein, mouse; D051034:Inhibitor of Apoptosis Proteins; D012333:RNA, Messenger; D012097:Repressor Proteins; D000077022:Survivin; D017239:Paclitaxel